

Joint AAD-NPF guidelines of care for the management of psoriasis with biologics

Journal of the American Academy of Dermatology
80, 1029-1072

DOI: [10.1016/j.jaad.2018.11.057](https://doi.org/10.1016/j.jaad.2018.11.057)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Psoriasis biologics: a new era of choice. Lancet, The, 2019, 394, 807-808.	13.7	13
2	Biosimilars for the treatment of psoriasis. Expert Opinion on Biological Therapy, 2019, 19, 993-1000.	3.1	30
3	Monoclonal antibodies for the treatment of plaque psoriasis. The Prescriber, 2019, 30, 35-40.	0.3	0
4	Update on Tildrakizumab for Psoriasis. Current Dermatology Reports, 2019, 8, 319-325.	2.1	1
5	Understanding Treatment Preferences in Patients with Moderate to Severe Plaque Psoriasis in the USA: Results from a Cross-Sectional Patient Survey. Dermatology and Therapy, 2019, 9, 785-797.	3.0	29
6	Risankizumab for the treatment of psoriasis. Expert Review of Clinical Pharmacology, 2019, 12, 851-857.	3.1	10
7	Tildrakizumab in the treatment of psoriasis: latest evidence and place in therapy. Therapeutic Advances in Chronic Disease, 2019, 10, 204062231986565.	2.5	11
8	Current Advances in the Prevention, Risk, and Management of Infection in Patients Receiving Biologic Therapy for Dermatologic Disorders. Current Dermatology Reports, 2019, 8, 141-148.	2.1	0
9	Managing Psoriasis in Patients with HBV or HCV Infection: Practical Considerations. American Journal of Clinical Dermatology, 2019, 20, 829-845.	6.7	28
10	Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence. BioDrugs, 2019, 33, 241-253.	4.6	34
11	Curative potential of hematopoietic stem cell transplantation for advanced psoriasis. American Journal of Hematology, 2019, 94, E176-E180.	4.1	5
12	Comment on "Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics". Journal of the American Academy of Dermatology, 2019, 81, e45.	1.2	2
13	Risankizumab in moderate-to-severe plaque psoriasis. Immunotherapy, 2019, 11, 1357-1370.	2.0	5
14	National Psoriasis Foundation: Planning for a Future Free of Psoriatic Disease and Its Burdens. Journal of Psoriasis and Psoriatic Arthritis, 2019, 4, 177-179.	0.7	1
15	The seroconversion rate of QuantiFERON-TB Gold In-Tube test in psoriatic patients receiving secukinumab and ixekizumab, the anti-interleukin-17A monoclonal antibodies. PLoS ONE, 2019, 14, e0225112.	2.5	18
16	The association between biologic agents and the risk of cardiovascular events in patients with psoriasis and psoriatic arthritis. Medicine (United States), 2019, 98, e18063.	1.0	3
17	Drug updates and approvals. Nurse Practitioner, 2019, 44, 21-32.	0.3	3
18	Interferon Kappa Is Up-Regulated in Psoriasis and It Up-Regulates Psoriasis-Associated Cytokines in vivo. Clinical, Cosmetic and Investigational Dermatology, 2019, Volume 12, 865-873.	1.8	7

#	ARTICLE	IF	CITATIONS
19	Risankizumab. Hospital Pharmacy, 2019, , 001857871987387.	1.0	1
20	A cross-sectional study of YouTube videos as a source of patient information about phototherapy and excimer laser for psoriasis. Journal of Dermatological Treatment, 2020, 31, 707-710.	2.2	12
21	Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. Journal of the American Academy of Dermatology, 2020, 82, 117-122.	1.2	120
22	Management of pediatric plaque psoriasis using biologics. Journal of the American Academy of Dermatology, 2020, 82, 213-221.	1.2	32
23	Is the concept of clinical equipoise maintained in psoriasis research?. Journal of Dermatological Treatment, 2020, 31, 1-1.	2.2	3
24	Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and) Tj ETQq1 1 0.784314 rgB.5/Overlosh 10 Tf 50	1.5	10
25	A Phase IV, Randomized, Double-Blind, Placebo-Controlled Crossover Study of the Effects of Ustekinumab on Vascular Inflammation in Psoriasis (the VIP-U Trial). Journal of Investigative Dermatology, 2020, 140, 85-93.e2.	0.7	83
26	Joint American Academy of Dermatologyâ€“National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. Journal of the American Academy of Dermatology, 2020, 82, 161-201.	1.2	129
27	Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis. Annals of Pharmacotherapy, 2020, 54, 380-387.	1.9	11
28	The prevalence of latent tuberculosis in dermatology patients on immunosuppressant therapy in New Orleans, Louisiana: A retrospective record review. Journal of the American Academy of Dermatology, 2020, 82, 1242-1243.	1.2	0
29	Ustekinumab does not increase tuberculosis risk: Results from a national database in South Korea. Journal of the American Academy of Dermatology, 2020, 82, 1243-1245.	1.2	16
30	Anti-TNF agent etanercept augments UV-induced skin cancer development in SKH-1 mice. Journal of Dermatological Treatment, 2021, 32, 812-818.	2.2	4
31	Chronic inflammation, cardiometabolic diseases and effects of treatment: Psoriasis as a human model. Trends in Cardiovascular Medicine, 2020, 30, 472-478.	4.9	49
32	Systematic literature review of non-topical treatments for early, untreated (systemic therapy naïve) psoriatic disease: a GRAPPA initiative. Rheumatology Advances in Practice, 2020, 4, rkaa032.	0.7	3
33	Comparing Medical Utilization and Cost Outcomes in Oral Versus Injectable Immunotherapy Users with Chronic Inflammatory Joint and Skin Diseases. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 1246-1256.	0.9	2
35	PSO-LONG: Design of a Novel, 12-Month Clinical Trial of Topical, Proactive Maintenance with Twice-Weekly Cal/BD Foam in Psoriasis. Advances in Therapy, 2020, 37, 4730-4753.	2.9	6
36	Comparison of psoriasis guidelines for use of IL-23 inhibitors in the United States and United Kingdom: a critical appraisal and comprehensive review. Journal of Dermatological Treatment, 2022, 33, 1252-1256.	2.2	4
37	Clinical efficacy and safety of secukinumab in patients with psoriasis and comorbidities: pooled analysis of 4 phase 3 clinical trials. Journal of Dermatological Treatment, 2022, 33, 1482-1490.	2.2	6

#	ARTICLE	IF	CITATIONS
38	Adjunctive Use of Calcipotriene/Betamethasone Dipropionate Foam in a Real-World Setting Curtails the Cost of Biologics Without Reducing Efficacy in Psoriasis. <i>Dermatology and Therapy</i> , 2020, 10, 1383-1396.	3.0	3
39	The real psoriasis biologics era will take some time in China. <i>Journal of Dermatological Treatment</i> , 2020, , 1-2.	2.2	0
40	Increased biologic utilization in Latino patients with psoriasis. <i>Journal of Dermatological Treatment</i> , 2020, , 1-4.	2.2	2
41	Practical compendium for psoriasis management. <i>Dermatologic Therapy</i> , 2020, 33, e13243.	1.7	4
42	Real-world switch patterns and healthcare costs in biologic-naïve psoriasis patients initiating apremilast or biologics. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 767-779.	1.4	8
43	Understanding and Minimising Injection-Site Pain Following Subcutaneous Administration of Biologics: A Narrative Review. <i>Rheumatology and Therapy</i> , 2020, 7, 741-757.	2.3	37
44	Choosing the right treatment for patients with psoriatic arthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2096262.	2.7	14
45	Multisociety and multispecialty clinical practice guidelines. <i>Archives of Dermatological Research</i> , 2022, 314, 311-316.	1.9	4
46	A Molecular Perspective on the Potential Benefits of Metformin for the Treatment of Inflammatory Skin Disorders. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8960.	4.1	23
47	Is chemoprophylaxis necessary for all latent tuberculosis infection patients receiving<sc>IL</sc> inhibitors? A cohort study. <i>Dermatologic Therapy</i> , 2020, 33, e14512.	1.7	13
48	Severe Acute Respiratory Syndrome Coronavirus 2 and the Use of Biologics in Patients With Psoriasis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020, 24, 625-632.	1.2	5
49	Unlocking the Value of Anti-TNF Biosimilars: Reducing Disease Burden and Improving Outcomes in Chronic Immune-Mediated Inflammatory Diseases: A Narrative Review. <i>Advances in Therapy</i> , 2020, 37, 3732-3745.	2.9	11
51	Predictors of Biologic Use and Satisfaction Among Patients With Psoriasis: An Analysis and Geographic Visualization of the 2016 and 2017 National Psoriasis Foundation Annual Surveys. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2020, 5, 100-108.	0.7	0
52	Chinese Experts Consensus on Biologic Therapy for Psoriasis#. <i>International Journal of Dermatology and Venereology</i> , 2020, 3, 76-85.	0.3	1
53	<p>Switch Rates and Total Cost of Care Associated with Apremilast and Biologic Therapies in Biologic-Naïve Patients with Plaque Psoriasis</p>. <i>ClinicoEconomics and Outcomes Research</i> , 2020, Volume 12, 369-377.	1.9	10
54	Severe COVIDâ€19 outcomes in patients with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e776-e778.	2.4	15
55	Oxidized Lipids and Lipoprotein Dysfunction in Psoriasis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2020, 5, 139-146.	0.7	6
56	The role of xenobiotics in triggering psoriasis. <i>Archives of Toxicology</i> , 2020, 94, 3959-3982.	4.2	8

#	ARTICLE	IF	CITATIONS
57	Tildrakizumab Shows Significant Efficacy in Psoriasis Treatment With Comorbid Immunoglobulin A Nephropathy: A Case Report. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2020, 5, 160-163.	0.7	0
58	A Real-World Evaluation of the Long-Term Safety and Efficacy of Infliximab in the Treatment Moderate-to-Severe Psoriasis. <i>Dermatology and Therapy</i> , 2020, 10, 1121-1135.	3.0	3
59	National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1704-1716.	1.2	43
60	Skin Test. <i>Journal of the Dermatology Nurses' Association</i> , 2020, 12, 181-184.	0.1	0
61	Calcipotriol/Betamethasone Dipropionate Cutaneous Foam Treatment for Psoriasis in Patients With BSA 5â€“15% and PGAâ€“3: Post-Hoc Analysis From Three Randomized Controlled Trials. <i>Dermatology and Therapy</i> , 2020, 10, 1111-1120.	3.0	4
62	The prevalence of SARS-CoV-2 infection and the severity of the course of COVID-19 in patients with psoriasis treated with biologic therapy. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1581-1584.	2.2	10
63	Impact of the COVID-19 Pandemic on Immunomodulatory and Immunosuppressive Therapies in Dermatology: Patient and Physician Attitudes in Argentina. <i>Actas Dermo-sifiligrÃ¡ficas</i> , 2020, 111, 806-807.	0.4	0
64	Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 360-368.	1.2	37
65	Disease response and patient-reported outcomes among initiators of ixekizumab. <i>Journal of Dermatological Treatment</i> , 2020, , 1-9.	2.2	6
66	Psoriasis: more than skin deep. <i>British Journal of Health Care Management</i> , 2020, 26, 134-137.	0.2	0
67	Association Between Psoriasis and Dementia: Current Evidence. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 570992.	3.4	20
68	Use of Anti-IL-17 Monoclonal Antibodies in HIV Patients with Erythrodermic Psoriasis. <i>Case Reports in Dermatology</i> , 2020, 12, 132-137.	0.8	25
69	Use of anti-IL 17A for psoriasis is not necessarily contraindicated in organ transplantation patients. <i>European Journal of Dermatology</i> , 2020, 30, 311-313.	0.6	6
70	Pathophysiology, Clinical Presentation, and Treatment of Psoriasis. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1945.	7.4	953
71	The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathwayâ€“inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 677-679.	1.2	46
72	Beyond skin deep: addressing comorbidities in psoriasis. <i>Medical Journal of Australia</i> , 2020, 212, 528-534.	1.7	30
73	Certolizumab for the treatment of psoriasis and psoriatic arthritis: a realâ€“world multicentre Italian study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2839-2845.	2.4	6
74	Pharmacotherapyâ€“and inappropriate prescriptions in patients with psoriasis. <i>International Journal of Clinical Pharmacy</i> , 2020, 42, 1270-1277.	2.1	3

#	ARTICLE	IF	CITATIONS
75	Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis. British Journal of Dermatology, 2020, 183, 638-649.	1.5	54
76	Brodalumab to the Rescue: Efficacy and Safety of Brodalumab in Patients with Psoriasis and Prior Exposure or Inadequate Response to Biologics. Dermatology and Therapy, 2020, 10, 615-621.	3.0	7
77	Metformin inhibits IL-1 β secretion via impairment of NLRP3 inflammasome in keratinocytes: implications for preventing the development of psoriasis. Cell Death Discovery, 2020, 6, 11.	4.7	52
78	Treatment guidelines in psoriatic arthritis. Rheumatology, 2020, 59, i37-i46.	1.9	111
79	Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis. Advances in Therapy, 2020, 37, 2098-2115.	2.9	6
80	Reduced Efficacy of Biological Drugs in Psoriatic Patients with HLA-A Bw4-80I KIR Ligands. Molecular Diagnosis and Therapy, 2020, 24, 311-314.	3.8	2
81	Biologic therapy for psoriasis during the covid-19 outbreak is not a choice. Journal of Dermatological Treatment, 2020, 31, 320-321.	2.2	28
82	Biological treatment use amid the COVID-19 era, a close look at the unresolved perplexity. Journal of Dermatological Treatment, 2020, 31, 322-323.	2.2	4
83	Therapeutic management of adults with atopic dermatitis: comparison with psoriasis and chronic urticaria. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2339-2345.	2.4	10
84	Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States. Journal of Dermatological Treatment, 2022, 33, 740-748.	2.2	5
85	Evidence and potential mechanisms of traditional Chinese medicine for the treatment of psoriasis vulgaris: a systematic review and meta-analysis. Journal of Dermatological Treatment, 2022, 33, 671-681.	2.2	11
86	Risankizumab: A Review in Moderate to Severe Plaque Psoriasis. Drugs, 2020, 80, 1235-1245.	10.9	21
87	A Nonsystematic Review on Risankizumab: a Novel Drug Recently Approved for Moderate to Severe Psoriasis. SN Comprehensive Clinical Medicine, 2020, 2, 1174-1180.	0.6	1
88	Dose optimization of brodalumab in moderate-to-severe plaque psoriasis: A case report. SAGE Open Medical Case Reports, 2020, 8, 2050313X2090567.	0.3	3
89	Biologic therapies for the treatment of hidradenitis suppurativa. Expert Opinion on Biological Therapy, 2020, 20, 621-633.	3.1	11
90	A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S). Journal of Investigative Dermatology, 2020, 140, 1784-1793.e2.	0.7	61
91	The safety of brodalumab for the treatment of psoriasis. Expert Opinion on Drug Safety, 2020, 19, 365-372.	2.4	16
92	Safety considerations with combination therapies for psoriasis. Expert Opinion on Drug Safety, 2020, 19, 489-498.	2.4	14

#	ARTICLE	IF	CITATIONS
93	How can we manage the safety concerns associated with the increase in biologics for psoriasis?. Expert Opinion on Drug Safety, 2020, 19, 361-364.	2.4	3
94	Risk of tuberculosis reactivation during interleukin-17 inhibitor therapy for psoriasis: a systematic review. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1449-1456.	2.4	42
96	Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis. JAMA Dermatology, 2020, 156, 649.	4.1	120
97	Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence. Dermatology and Therapy, 2020, 10, 351-364.	3.0	18
98	Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results from three phase 3 trials. Journal of Dermatological Treatment, 2022, 33, 261-265.	2.2	29
99	Art of prevention: Our approach to the measles-mumps-rubella vaccine in adult patients vaccinated against measles before 1968 on biologic therapy for the treatment of psoriasis. International Journal of Women's Dermatology, 2020, 6, 94-96.	2.0	4
100	Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltimMa-1 and UltimMa-2 studies. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2830-2838.	2.4	46
101	Response to Inhibition of Receptor-Interacting Protein Kinase 1 (RIPK1) in Active Plaque Psoriasis: A Randomized Placebo-Controlled Study. Clinical Pharmacology and Therapeutics, 2020, 108, 808-816.	4.7	46
102	The unforeseen during biotechnological therapy for moderate-to-severe psoriasis: How to manage pregnancy and breastfeeding, infections from Mycobacterium tuberculosis, hepatitis B virus, hepatitis C virus, and HIV, surgery, vaccinations, diagnosis of malignancy, and dose tapering. Dermatologic Therapy, 2020, 33, e13411.	1.7	4
103	Role of phototherapy in the era of biologics. Journal of the American Academy of Dermatology, 2021, 84, 479-485.	1.2	48
104	Use of systemic therapies for psoriasis in the COVID-19 era. Journal of Dermatological Treatment, 2021, 1-4.	2.2	10
105	Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies. British Journal of Dermatology, 2021, 184, 640-651.	1.5	16
106	Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent. Journal of the American Academy of Dermatology, 2021, 84, 1059-1067.	1.2	92
107	Efficacy and safety of Risankizumab in moderate to severe psoriasis: A systematic review and meta-analysis. Dermatologic Therapy, 2021, 34, e14487.	1.7	15
108	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Annals of the Rheumatic Diseases, 2021, 80, 71-87.	0.9	158
109	Axial psoriatic arthritis: An update for dermatologists. Journal of the American Academy of Dermatology, 2021, 84, 92-101.	1.2	41
110	Tumor Necrosis Factor Inhibitors. , 2021, , 287-301.e7.		2
111	Dermatologic Drug Therapy in Children. , 2021, , 767-776.e3.		0

#	ARTICLE	IF	CITATIONS
112	Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2). British Journal of Dermatology, 2021, 184, 652-662.	1.5	15
113	Association of Nail Psoriasis With Disease Activity Measures and Impact in Psoriatic Arthritis: Data From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. Journal of Rheumatology, 2021, 48, 520-526.	2.0	14
114	Age-appropriate cancer screening: A cohort study of adults with psoriasis prescribed biologics, adults in the general population, and adults with hypertension. Journal of the American Academy of Dermatology, 2021, 84, 1602-1609.	1.2	6
115	Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 938-947.	2.4	61
116	Relationship between serum trough levels and efficacy of brodalumab from a post hoc exploratory analysis of a Japanese study in patients with plaque psoriasis. Journal of Dermatology, 2021, 48, 324-333.	1.2	1
117	Immunogenicity of Biologic and Biosimilar Therapies for Psoriasis and Impact of Novel Immunoassays for Immunogenicity Detection. American Journal of Clinical Dermatology, 2021, 22, 221-231.	6.7	2
118	An update on the impact of depression on the treatment of psoriasis. Expert Opinion on Pharmacotherapy, 2021, 22, 695-703.	1.8	9
119	Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review. American Journal of Clinical Dermatology, 2021, 22, 173-192.	6.7	79
120	Spondylitis-psoriasis-enthesitis-enterocolitis-dactylitis-uveitis-peripheral synovitis (SPEED-UP) treatment. Autoimmunity Reviews, 2021, 20, 102731.	5.8	15
121	Psoriasis drugs in the medicare population: dermatologists' spending and prescription patterns. Journal of Dermatological Treatment, 2022, 33, 1758-1761.	2.2	3
122	Rapid Response to Certolizumab Pegol in Hidradenitis Suppurativa: A Case Report. Skin Appendage Disorders, 2021, 7, 58-61.	1.0	16
123	Association of COVID-19 with skin diseases and relevant biologics: a cross-sectional study using nationwide claim data in South Korea*. British Journal of Dermatology, 2021, 184, 296-303.	1.5	14
124	Anti-tumor necrosis factor agents in psoriasis: addressing key challenges using biosimilars. Expert Opinion on Biological Therapy, 2021, 21, 75-80.	3.1	9
125	miR-146b correlates with increased disease activity and psoriatic tissue inflammation and promotes keratinocyte proliferation in psoriasis. Experimental and Therapeutic Medicine, 2021, 21, 296.	1.8	2
126	Biologic Drugs for the Treatment of Noninfectious Uveitis. Asia-Pacific Journal of Ophthalmology, 2021, 10, 63-73.	2.5	5
127	Add-on effect of PSORI-CM01 to topical calcipotriol for moderate psoriasis vulgaris: A multicenter, randomized, double-blind pilot study. Clinical and Translational Medicine, 2021, 11, e286.	4.0	5
128	Cardiovascular Side Effects of Medications for Skin Diseases. , 2021, , 391-418.		0
129	Long-term safety of combination treatment with methotrexate and tumor necrosis factor (TNF) antagonists versus TNF antagonists alone in psoriatic patients. Journal of Dermatology, 2021, 48, 835-843.	1.2	6

#	ARTICLE	IF	CITATIONS
130	IL-17 Inhibitors and Inflammatory Bowel Diseases: A Postmarketing Study in Vigibase. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 159-168.	4.7	28
131	PASI 100 response rates in moderate to severe psoriasis: a systematic literature review and analysis of clinical practice guidelines. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1661-1669.	2.2	15
132	IL-17A inhibitors in patients with chronic plaque psoriasis and history of malignancy: A case series with systematic literature review. <i>Dermatologic Therapy</i> , 2021, 34, e14889.	1.7	14
133	Brodalumab in an Organ Transplant Recipient With Psoriasis. , 2021, 107, 104-106.		7
134	Two cases of refractory erythrodermic psoriasis effectively treated with secukinumab and a review of the literature. <i>Dermatologic Therapy</i> , 2021, 34, e14825.	1.7	6
135	Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 797-806.	2.4	6
136	Exploring determinants of psoriasis patients' treatment choices: a discrete-choice experiment study in the United States and Germany. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1511-1520.	2.2	4
137	Nail Psoriasis: Diagnosis, Assessment, Treatment Options, and Unmet Clinical Needs. <i>Journal of Rheumatology</i> , 2021, 48, 1208-1220.	2.0	17
138	Clinical Epidemiology and Management of Hidradenitis Suppurativa. <i>Obstetrics and Gynecology</i> , 2021, 137, 731-746.	2.4	10
139	Psoriatic arthritis: the role of the nonphysician clinician in the diagnosis and treatment of patients with psoriasis. <i>Drugs and Therapy Perspectives</i> , 2021, 37, 162-174.	0.6	1
140	Low rate of conversion to positive tuberculosis status among patients with psoriasis on biologic therapies: A retrospective study from a US academic medical center. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 830-833.	1.2	3
141	Utility of the Dermatology Life Quality Index at initiation or switching of biologics in real-life Japanese patients with plaque psoriasis: Results from the ProLOGUE study. <i>Journal of Dermatological Science</i> , 2021, 101, 185-193.	1.9	19
142	Pattern of use of biologics in psoriasis among Indian dermatologists – A cross sectional survey. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2021, .	0.6	1
143	Oral and Topical Vitamin D, Sunshine, and UVB Phototherapy Safely Control Psoriasis in Patients with Normal Pretreatment Serum 25-Hydroxyvitamin D Concentrations: A Literature Review and Discussion of Health Implications. <i>Nutrients</i> , 2021, 13, 1511.	4.1	5
144	Association of Patient Mental Health Status With the Level of Agreement Between Patient and Physician Ratings of Psoriasis Severity. <i>JAMA Dermatology</i> , 2021, 157, 413.	4.1	18
145	Efficacy, tolerability, patient usability, and satisfaction with a 2-mL pre-filled syringe containing secukinumab 300-mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1718-1726.	2.2	6
146	Biologics recommendations for patients with psoriasis: a critical appraisal of clinical practice guidelines for psoriasis. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2038-2050.	2.2	7
147	Psoriasis. <i>Lancet, The</i> , 2021, 397, 1301-1315.	13.7	792

#	ARTICLE	IF	CITATIONS
148	Incidence of Venous Thromboembolism in Patients With Dermatologist-Diagnosed Chronic Inflammatory Skin Diseases. JAMA Dermatology, 2021, 157, 805.	4.1	21
149	Comparison of guidelines for the use of Ustekinumab for psoriasis in the United States, Europe, and the United Kingdom: A critical appraisal and comprehensive review. Dermatologic Therapy, 2021, 34, e14974.	1.7	2
150	Alcohol in Psoriasisâ€”From Bench to Bedside. International Journal of Molecular Sciences, 2021, 22, 4987.	4.1	8
151	Practical management of patients on anti-IL17 therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI). Joint Bone Spine, 2021, 88, 105210.	1.6	0
152	Apremilast as an Off-Label Therapeutic Agent. SKIN the Journal of Cutaneous Medicine, 2021, 5, 203-227.	0.3	1
153	Incidence and prognosis of COVIDâ€“19 in psoriasis patients on biologic therapy: a multicentre retrospective cohort study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e485-e487.	2.4	6
154	Quality of Life in Patients with Skin Disease and Their Cohabitants. , 0, , .		0
155	Immunotherapy in psoriasis. Immunotherapy, 2021, 13, 605-619.	2.0	10
156	A safety review of biologic therapies for the management of hidradenitis suppurativa and unmet needs. Expert Opinion on Drug Safety, 2021, 20, 1147-1161.	2.4	6
157	Dynamic Visual Representation of Clinical Efficacy of Ixekizumab in Psoriasis. Dermatology and Therapy, 2021, 11, 1107-1118.	3.0	1
158	Fiveâ€“year efficacy and safety of tildrakizumab in patients with moderateâ€“toâ€“severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)*. British Journal of Dermatology, 2021, 185, 323-334.	1.5	55
159	Practical management of patients on anti-TNF therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI). Joint Bone Spine, 2021, 88, 105174.	1.6	0
160	Psoriasis is associated with fissured tongue but not geographic tongue: a prospective, crossâ€“sectional, caseâ€“control study. JDDG - Journal of the German Society of Dermatology, 2021, 19, 1170-1176.	0.8	4
161	Treatments and outcomes of generalized pustular psoriasis: A cohort of 1516 patients in a nationwide inpatient database in Japan. Journal of the American Academy of Dermatology, 2022, 86, 1266-1274.	1.2	57
162	Polymorphisms in GNMT and DNMT3b are associated with methotrexate treatment outcome in plaque psoriasis. Biomedicine and Pharmacotherapy, 2021, 138, 111456.	5.6	13
163	Recommendations for Vaccination in Children with Atopic Dermatitis Treated with Dupilumab: A Consensus Meeting, 2020. American Journal of Clinical Dermatology, 2021, 22, 443-455.	6.7	10
164	A clinical perspective on risk factors and signs of subclinical and early psoriatic arthritis among patients with psoriasis. Journal of Dermatological Treatment, 2022, 33, 1907-1915.	2.2	6
165	Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety. , 2022, 229, 107925.		16

#	ARTICLE	IF	CITATIONS
166	Perkembangan Terkini Terapi Sistemik Psoriasis. Jurnal Kedokteran Meditek, 2021, 27, 136-146.	0.0	0
167	Psoriasis Severity, Comorbidities, and Treatment Response Differ among Geographic Regions in the United States. JID Innovations, 2021, 1, 100025.	2.4	9
168	Reaching Treatment Goals in Psoriasis with Conventional Systemic Drugs: How Long Are We Willing to Wait?. Dermatology, 2022, 238, 292-300.	2.1	0
169	Fixed-Combination Halobetasol Propionate and Tazarotene in the Treatment of Psoriasis: Narrative Review of Mechanisms of Action and Therapeutic Benefits. Dermatology and Therapy, 2021, 11, 1157-1174.	3.0	4
170	Correlation Between Change in Psoriasis Area and Severity Index and Dermatology Life Quality Index in Patients with Psoriasis: Pooled Analysis from Four Phase-3 Clinical Trials of Secukinumab. Dermatology and Therapy, 2021, 11, 1373-1384.	3.0	11
171	Effectiveness of IL-23 Inhibitor Guselkumab in Real-World Chinese Patients with Psoriasis During a 20-Week Period. Psoriasis: Targets and Therapy, 2021, Volume 11, 53-58.	2.2	6
172	Viewing Psoriasis as a Systemic Disease for Better Health Outcomes. JID Innovations, 2021, 1, 100007.	2.4	2
173	Overuse of Tuberculosis Surveillance Testing in Patients With Inflammatory Bowel Disease Compared to Non-IBD Patients on Biologic Therapy. Crohn's & Colitis 360, 2021, 3, .	1.1	2
174	Risk of psoriasis according to body mass index: A retrospective cohort analysis. Journal of the American Academy of Dermatology, 2022, 86, 1020-1026.	1.2	19
175	Psoriasis treatment patterns and outcomes with ixekizumab in a real-world setting: results from a single US dermatology referral practice. Journal of Dermatological Treatment, 2021, , 1-7.	2.2	1
176	Neutrophils as Drivers of Immune Dysregulation in Autoimmune Diseases with Skin Manifestations. Journal of Investigative Dermatology, 2022, 142, 823-833.	0.7	16
177	Dermatological manifestations associated with COVID-19: A comprehensive review of the current knowledge. Journal of Medical Virology, 2021, 93, 5756-5767.	5.0	26
178	Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: A prospective analysis in Corrona Psoriasis Registry. Journal of the American Academy of Dermatology, 2022, 86, 68-76.	1.2	22
179	Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Journal of the American Academy of Dermatology, 2022, 86, 77-85.	1.2	21
180	Periodontal and dental health in inflammatory bowel diseases: a systematic review. Expert Review of Gastroenterology and Hepatology, 2021, , 1-15.	3.0	8
181	The Impact of Smoking on Psoriasis Patients with Biological Therapies in a Bucharest Hospital. Journal of Personalized Medicine, 2021, 11, 752.	2.5	3
182	Switching TNF α inhibitors: Patterns and determinants. Pharmacology Research and Perspectives, 2021, 9, e00843.	2.4	3
183	Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINE-2 and AMAGINE-3. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 2034-2044.	2.4	6

#	ARTICLE	IF	CITATIONS
184	A Survey of Community Dermatologists Reveals the Unnecessary Impact of Trial-and-Error Behavior on the Psoriasis Biologic Treatment Paradigm. <i>Dermatology and Therapy</i> , 2021, 11, 1851-1860.	3.0	8
185	Saudi consensus statement on biologic treatment of chronic plaque psoriasis (2020). <i>Journal of Dermatological Treatment</i> , 2021, , 1-15.	2.2	1
186	Newer Therapies in Psoriasis. <i>Medical Clinics of North America</i> , 2021, 105, 627-641.	2.5	10
187	Disease burden, symptoms, and use of analgesics in patients with psoriasis with or without psoriatic arthritis: A cross-sectional study. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 590-597.	1.2	8
188	Treatment Patterns and Resource Utilization of Pregnant Women with Inflammatory Rheumatic Diseases or Psoriasis in Germany: A Claims Database Analysis. <i>Rheumatology and Therapy</i> , 2021, 8, 1565-1584.	2.3	2
189	Real-World Satisfaction with Secukinumab in Clearing the Skin of Patients with Plaque Psoriasis through 24 Months of Follow-Up: Results from US Dermatology Electronic Medical Records. <i>Dermatology and Therapy</i> , 2021, 11, 1733-1749.	3.0	5
190	Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 2398-2408.	2.4	4
191	A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab. <i>Frontiers in Medicine</i> , 2021, 8, 702776.	2.6	9
192	Combination treatment with monoclonal antibodies: Secukinumab, benralizumab and dupilumab for the combined management of psoriasis and severe asthma. <i>Australasian Journal of Dermatology</i> , 2021, 62, 506-508.	0.7	10
194	Innate Immune Regulation of Dermatitis. <i>Immunology and Allergy Clinics of North America</i> , 2021, 41, 347-359.	1.9	8
195	Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2*. <i>British Journal of Dermatology</i> , 2021, 185, 1146-1159.	1.5	36
196	Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 572-581.	1.2	36
197	T-cell subsets in the skin and their role in inflammatory skin disorders. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 827-842.	5.7	27
198	Real-world effectiveness of guselkumab in patients with psoriasis: Health-related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial. <i>Journal of Dermatology</i> , 2021, 48, 1854-1862.	1.2	24
199	Incidence and prevalence of psoriatic arthritis in patients with psoriasis stratified by psoriasis disease severity: Retrospective analysis of an electronic health records database in the United States. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 748-757.	1.2	20
200	Challenge of Nail Psoriasis: An Update Review. <i>Clinical Reviews in Allergy and Immunology</i> , 2021, 61, 377-402.	6.5	17
201	New Frontiers in Psoriatic Disease Research, Part II: Comorbidities and Targeted Therapies. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2328-2337.	0.7	21
203	Visit Adherence of Mild to Moderate Psoriasis Patients: A Mobile-Based Randomized Study. <i>Patient Preference and Adherence</i> , 2020, Volume 14, 2551-2557.	1.8	2

#	ARTICLE	IF	CITATIONS
204	Lipid-based nanoparticles for psoriasis treatment: a review on conventional treatments, recent works, and future prospects. RSC Advances, 2021, 11, 29080-29101.	3.6	24
205	Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: a review of real-world evidence (RWE). Journal of Dermatological Treatment, 2021, 32, 883-893.	2.2	11
206	Cupping for psoriasis vulgaris. Medicine (United States), 2020, 99, e20348.	1.0	1
207	Conversion and Reversion Rates of Tuberculosis Screening Assays in Patients With Rheumatic Diseases and Negative Baseline Screening Under Long-Term Biologic Treatment. Pathogens and Immunity, 2020, 5, 34.	3.1	9
208	Psoriasis and Genetics. Acta Dermato-Venereologica, 2020, 100, 55-65.	1.3	64
209	Treatment of psoriasis: janus kinases inhibitors and biologics for the interleukin-23/Th17 axis. Minerva Medica, 2020, 111, 254-265.	0.9	4
210	Transitioning Between Biologics. SKIN the Journal of Cutaneous Medicine, 2019, 3, 374-380.	0.3	3
211	Infections in Patients with Rheumatoid Arthritis in the Era of Targeted Synthetic Therapies. Mediterranean Journal of Rheumatology, 2020, 31, 129.	0.8	16
212	Medical and social care program for patients with psoriasis and/or psoriatic arthritis eligible for biological dmards in real clinical practice. Nauchno-Prakticheskaya Revmatologiya, 2020, 58, 495-502.	1.0	2
213	Therapeutic goals and treatment response evaluation in moderate to severe psoriasis: an experts opinion document. Annals of Medicine, 2021, 53, 1727-1736.	3.8	4
214	Characterizing Outcomes and Unmet Needs Among Patients in the United States with Mild-to-Moderate Plaque Psoriasis Using Prescription Topicals. Dermatology and Therapy, 2021, 11, 2057-2075.	3.0	7
216	Evaluaci3n de la calidad de gu3as de pr3ctica cl3nica para el tratamiento de psoriasis mediante la herramienta AGREE II. Actas Dermo-sifiliogr3ficas, 2022, 113, 222-235.	0.4	1
217	Cutaneous and Systemic Psoriasis: Classifications and Classification for the Distinction. Frontiers in Medicine, 2021, 8, 649408.	2.6	18
218	Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18Months. Dermatology and Therapy, 2021, 11, 2133-2145.	3.0	3
219	Pustular Psoriasis: A Narrative Review of Recent Developments in Pathophysiology and Therapeutic Options. Dermatology and Therapy, 2021, 11, 1917-1929.	3.0	34
220	Management of pediatric generalized pustular psoriasis using biologics: An evidence-based review. Journal of the American Academy of Dermatology, 2022, 87, 484-486.	1.2	4
222	Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey. Dermatology and Therapy, 2022, 12, 61-78.	3.0	18
223	Variation In Use And Content Of Prescription Drug Step Therapy Protocols, Within And Across Health Plans. Health Affairs, 2021, 40, 1749-1757.	5.2	10

#	ARTICLE	IF	CITATIONS
224	The effectiveness and safety study of topical corticosteroids for psoriasis in adolescent and adult population treatment. ZaporoÅ¼skij Medicinskij Å½urnal, 2020, .	0.2	0
225	Portuguese recommendations for the treatment of psoriasis with biologic therapy. European Journal of Dermatology, 2020, 30, 645-654.	0.6	4
226	Therapeutic and Prophylactic Effects of Honey on Dermatitis and Related Disorders. , 2020, , 249-272.		0
228	A Machine Learning-Based Test for Predicting Response to Psoriasis Biologics. SKIN the Journal of Cutaneous Medicine, 2021, 5, 621-638.	0.3	6
229	Realâ€world, longâ€term treatment patterns of commonly used biologics in Canadian patients with moderateâ€toâ€severe chronic plaque psoriasis. Journal of Dermatology, 2022, 49, 95-105.	1.2	11
230	Ustekinumab safety in pregnancy: a comprehensive review. Arthritis Care and Research, 2021, , .	3.4	3
232	Adalimumab for Psoriasis. , 2021, , 153-172.		0
233	Risankizumab. , 2021, , 235-241.		0
235	Research Pipeline II: Upcoming Biologic Therapies. , 2021, , 303-310.		0
236	Traditional Systemic Therapy I: Methotrexate and Cyclosporine. , 2021, , 103-118.		0
237	General practice recommendations for the topical treatment of psoriasis: a modified-Delphi approach. BJGP Open, 2020, 4, bjgpopen20X101108.	1.8	11
238	Systemic treatment of psoriasis: from methotrexate to biologics. Vestnik Dermatologii i Venerologii, 2020, 96, 7-26.	0.6	6
239	Recommendations for Initiating Systemic Therapy in Patients with Psoriasis. Journal of Clinical and Aesthetic Dermatology, 2019, 12, 13-26.	0.1	4
240	Prescribing Patterns Associated With Biologic Therapies for Psoriasis from a United States Medical Records Database. Journal of Drugs in Dermatology, 2019, 18, 745-750.	0.8	5
241	Structural Basis for How Biologic Medicines Bind their Targets in Psoriasis Therapy. Yale Journal of Biology and Medicine, 2020, 93, 19-27.	0.2	1
242	Current Developments in the Immunology of Psoriasis. Yale Journal of Biology and Medicine, 2020, 93, 97-110.	0.2	56
243	Randomised, double-blind, multicentre, phase â€¦/â€¦ dose escalation and expansion trial of GR1501 in patients with plaque psoriasis: study protocol. BMJ Open, 2020, 10, e039067.	1.9	1
244	Systemic Management of Psoriasis Patients in Indian Scenario: An Expert Consensus. Indian Dermatology Online Journal, 2021, 12, 674-682.	0.5	0

#	ARTICLE	IF	CITATIONS
245	Comparison of noninvasive screening tools for hepatic fibrosis, association with methotrexate cumulative dose, and risk factors in psoriasis patients. <i>Dermatologic Therapy</i> , 2022, 35, e15203.	1.7	4
246	Nutritional factors in the pathogenesis and treatment of psoriasis in children. <i>Russian Pediatric Journal</i> , 2021, 24, 348-355.	0.2	0
247	Association between baseline insulin resistance and psoriasis incidence: the Women's Health Initiative. <i>Archives of Dermatological Research</i> , 2021, , 1.	1.9	4
248	Copy Number Variation Analysis of IL22 and LCE3C in Different Subtypes of Psoriasis in a Chinese Han Population. <i>Medical Science Monitor</i> , 2021, 27, e934927.	1.1	3
249	Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: Effect of Demographics and Baseline Disease Characteristics on Efficacy. <i>Dermatology and Therapy</i> , 2022, 12, 121-135.	3.0	2
250	Association between different systemic therapies and the risk of tuberculosis in psoriasis patients: A population-based study. <i>International Journal of Clinical Practice</i> , 2021, 75, e15006.	1.7	5
251	Psoriatic Arthritis: The Influence of Co-morbidities on Drug Choice. <i>Rheumatology and Therapy</i> , 2022, 9, 49-71.	2.3	3
252	Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas™ Psoriasis Registry. <i>Dermatology and Therapy</i> , 2022, 12, 97-119.	3.0	3
253	Systemic management of psoriasis patients in Indian scenario: An expert consensus. <i>Indian Dermatology Online Journal</i> , 2021, 12, 674.	0.5	8
255	Randomised, double-blind, multicentre, phase â.../â...; dose escalation and expansion trial of GR1501 in patients with plaque psoriasis: study protocol. <i>BMJ Open</i> , 2020, 10, e039067.	1.9	3
256	Severity of psoriasis â€ Time to disentangle severity from symptom control. <i>British Journal of Dermatology</i> , 2022, , .	1.5	0
257	Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management. <i>Psoriasis: Targets and Therapy</i> , 2022, Volume 12, 1-14.	2.2	7
258	Psoriasis and Cardiovascular Diseaseâ€An Ounce of Prevention Is Worth a Pound of Cure. <i>JAMA Dermatology</i> , 2022, 158, 239.	4.1	7
259	Treatment Patterns and Pharmacoutilization in Patients Affected by Psoriasis: An Observational Study in an Italian Real-World Setting. <i>Drugs - Real World Outcomes</i> , 2022, 9, 243-251.	1.6	3
260	Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study. <i>Dermatology and Therapy</i> , 2022, 12, 561-575.	3.0	7
261	It Is Time to Focus on Pustular Psoriasis. <i>JAMA Dermatology</i> , 2022, 158, 13.	4.1	2
262	A real-life experience as a proof of Guselkumab effectiveness and safety in patients with moderate to severe psoriasis. <i>Dermatologic Therapy</i> , 2022, 35, e15339.	1.7	8
263	Risk for HepatitisÂB Virus Reactivation in Patients with Psoriasis Treated with Biological Agents: A Systematic Review and Meta-Analysis. <i>Dermatology and Therapy</i> , 2022, 12, 655-670.	3.0	4

#	ARTICLE	IF	CITATIONS
264	Effectiveness and Safety of Secukinumab for Psoriasis in a Real-World Clinical Setting in the Asia-Pacific and Middle East Regions: Results from the REALIA Study. <i>Dermatology and Therapy</i> , 2022, 12, 511-527.	3.0	6
265	Systemic Treatments for Adult Patients with Moderate-to-Severe Psoriasis: Consensus Statements for the United Arab Emirates. <i>Emirates Medical Journal</i> , 2022, 3, 17-34.	0.3	0
266	Quality Assessment of Clinical Practice Guidelines on the Treatment of Psoriasis Using the AGREE II Tool. <i>Actas Dermo-sifiliográficas</i> , 2022, , .	0.4	1
267	[Translated article] Practical Update of the Recommendations Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis with Biologic Therapy. Part 1. Concepts and General Management of Psoriasis With Biologic Therapy. <i>Actas Dermo-sifiliográficas</i> , 2022, 113, T261-T277.	0.4	4
268	Systematic review and critical appraisal of psoriasis clinical practice guidelines: a Global Guidelines in Dermatology Mapping Project (<scp>GUIDEMAP</scp>)*. <i>British Journal of Dermatology</i> , 2022, 187, 178-187.	1.5	7
269	Treating patients with moderate-to-severe psoriasis vulgaris. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2022, Publish Ahead of Print, .	0.3	2
270	Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2021, 385, 2219-2229.	27.0	93
271	Comparison of Guidelines for the Use of Interleukin-17 Inhibitors for Psoriasis in the United States, Britain, and Europe: A Critical Appraisal and Comprehensive Review. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2021, 14, 55-59.	0.1	0
278	Response to Vaccines in Patients with Immune-Mediated Inflammatory Diseases: A Narrative Review. <i>Vaccines</i> , 2022, 10, 297.	4.4	14
279	Characteristics of New Biologic Users Among the Moderate-to-Severe Psoriasis Populationâ€”Retrospective Cohort Study Leveraging the Modernizing Medicine Data Services Database. <i>Dermatology and Therapy</i> , 2022, 12, 741-752.	3.0	0
280	Review article: paradoxical psoriasis as a consequence of tumour necrosis factor antagonists in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, , .	3.7	0
281	Diagnosis and Management of Plantar Dermatoses. <i>Journal of the American Board of Family Medicine</i> , 2022, 35, 435-442.	1.5	1
282	Impact of fixed-dose combination Cal/BD foam on the work productivity of patients with psoriasis: results from the 52-week randomized, double-blind, PSOâ€“LONG trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, , .	2.4	0
283	Risk of Treatment Discontinuation among Patients with Psoriasis Initiated on Ustekinumab and Other Biologics in the USA. <i>Dermatology and Therapy</i> , 2022, 12, 971.	3.0	3
284	Effectiveness of brodalumab in achieving treatment satisfaction for patients with plaque psoriasis: The ProLOGUE study. <i>Journal of Dermatological Science</i> , 2022, 105, 176-184.	1.9	12
285	Malignant melanoma in a psoriasis patient after sequential treatment with biologics. <i>Dermatologic Therapy</i> , 2022, 35, e15435.	1.7	4
286	Unmet Needs in the Management of Moderate-to-Severe Psoriasis in Spain: A Multidimensional Evaluation. <i>Acta Dermato-Venereologica</i> , 2022, 102, adv00678.	1.3	4
287	Biosimilar versus originator etanercept: a real-life clinical study. <i>Italian Journal of Dermatology and Venereology</i> , 2022, 157, .	0.2	2

#	ARTICLE	IF	CITATIONS
288	Current advances in biological therapy of psoriasis: efficacy of guselkumab in real clinical practice. Meditsinskiy Sovet, 2022, , 71-78.	0.5	0
289	Population-Based Study Detailing Cutaneous Melanoma Incidence and Mortality Trends in Canada. Frontiers in Medicine, 2022, 9, 830254.	2.6	13
290	Clinical Decisions in Pediatric Psoriasis. Dermatologic Clinics, 2022, 40, 145-166.	1.7	0
291	A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence. International Journal of Clinical Pharmacy, 2022, 44, 725-730.	2.1	6
292	Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection. Journal of Dermatological Treatment, 2022, 33, 2629-2633.	2.2	8
293	Practical and Relevant Guidelines for the Management of Psoriasis: An Inference-Based Methodology. Dermatology and Therapy, 2022, 12, 253-265.	3.0	2
294	Long-Term Benefitâ€“Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis. Dermatology and Therapy, 2022, 12, 167-184.	3.0	22
296	Healthcare Providers Face Numerous Challenges in Treating Patients with Psoriasis: Results from a Mixed-Methods Study. Journal of Psoriasis and Psoriatic Arthritis, 2022, 7, 35-43.	0.7	1
297	Chapter 41: Dermatologic Disorders. , 2022, , .		0
298	Conversion rate of tuberculosis screening tests among dermatology patients treated with tumor necrosis factor inhibitors. Indian Journal of Dermatology, 2022, 67, 1.	0.3	0
299	Secukinumab Therapy in Psoriasis Management. Berkala Ilmu Kesehatan Kulit Dan Kelamin, 2022, 34, 59-65.	0.2	1
300	Long-term Persistence of First-line Biologics for Patients With Psoriasis and Psoriatic Arthritis in the French Health Insurance Database. JAMA Dermatology, 2022, 158, 513.	4.1	27
301	Geographic Patterns in Psoriasis: An Observational Study of CorEvitas Psoriasis Registry. Journal of Psoriasis and Psoriatic Arthritis, 0, , 247553032210817.	0.7	0
302	Classification of human chronic inflammatory skin disease based on single-cell immune profiling. Science Immunology, 2022, 7, eabl9165.	11.9	53
303	Treatment Goals for Psoriasis as Measured by Patient Benefit Index: Results of a National Psoriasis Foundation Survey. Advances in Therapy, 2022, 39, 2657-2667.	2.9	7
304	Risk of hepatitisÂ“B reactivation: From biologic therapies for psoriasis to immunosuppressive therapies for COVIDâ€“19 (Review). Experimental and Therapeutic Medicine, 2022, 23, 385.	1.8	4
308	Tepilamide Fumarate (PPC-06) Extended Release Tablets in Patients with Moderate-to-Severe Plaque Psoriasis: Safety and Efficacy Results from the Randomized, Double-blind, Placebo-controlled AFFIRM Study.. Journal of Clinical and Aesthetic Dermatology, 2022, 15, 53-58.	0.1	0
309	Machine learning reveals distinct gene signature profiles in lesional and nonlesional regions of inflammatory skin diseases. Science Advances, 2022, 8, eabn4776.	10.3	15

#	ARTICLE	IF	CITATIONS
310	Reactivation rates of hepatitis B or C or HIV in patients with psoriasis using biological therapies: a systematic review and meta-analysis. <i>Clinical and Experimental Medicine</i> , 2023, 23, 701-715.	3.6	1
311	Cutaneous nerve fibers participate in the progression of psoriasis by linking epidermal keratinocytes and immunocytes. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 267.	5.4	9
312	Utilization Trends and Impact of Secukinumab Treatment on Clinical Outcomes in Biologic-Naive Patients with Psoriasis in a US Real-World Setting. <i>Dermatology and Therapy</i> , 2022, 12, 1351-1365.	3.0	2
313	Use of biological agents. <i>Turkderm</i> , 0, , 29-32.	0.1	0
315	Should Mammography Be a Prerequisite Prior to Initiation of Biological Agents in Patients With Psoriasis?. <i>Dermatology Practical and Conceptual</i> , 0, , e2022081.	0.9	0
319	Ixekizumab. <i>Turkderm</i> , 0, , 55-57.	0.1	0
320	Cognitive Functions Associated with Brain Imaging Markers in Patients with Psoriasis. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 5687.	2.6	4
321	Biologic initiation rates in systemic-naive psoriasis patients after first-line apremilast versus methotrexate use. <i>Journal of Comparative Effectiveness Research</i> , 2022, 11, 575-582.	1.4	1
322	Interleukin-23 Inhibitors. <i>Turkderm</i> , 0, , 61-66.	0.1	0
323	Certolizumab. <i>Turkderm</i> , 0, , 45-47.	0.1	0
324	Real-World Biologic Adherence, Persistence, and Monotherapy Comparisons in US Patients with Psoriasis: Results from IBM MarketScan® Databases. <i>Advances in Therapy</i> , 2022, 39, 3214-3224.	2.9	7
325	Efficacy, quality of life, and treatment satisfaction: an indirect comparison of calcipotriol/betamethasone dipropionate cream versus foam for treatment of psoriasis. <i>Current Medical Research and Opinion</i> , 2022, 38, 1521-1529.	1.9	5
326	Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over 2 years of follow-up in real-world settings. <i>Journal of Medical Economics</i> , 2022, 25, 741-749.	2.1	1
327	The Tuberculosis Positive Conversion Rate Among Psoriasis Patients Treated with Adalimumab and Secukinumab: A Single-Center Retrospective Study in China. <i>Dermatology and Therapy</i> , 2022, 12, 1493-1500.	3.0	3
328	Risks of Biologic Therapy and the Importance of Multidisciplinary Approach for an Accurate Management of Patients with Moderate-Severe Psoriasis and Concomitant Diseases. <i>Biology</i> , 2022, 11, 808.	2.8	2
329	Dermatology: how to manage psoriasis and recognize differences in pathophysiology and presentation in patients with skin of colour. <i>Drugs in Context</i> , 0, 11, 1-12.	2.2	5
330	Association between psoriasis and short-term outcomes of acute myocardial infarction: A matched-pair cohort study using a nationwide inpatient database in Japan. <i>JAAD International</i> , 2022, 8, 21-30.	2.2	3
331	Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection. <i>Clinical Drug Investigation</i> , 2022, 42, 525-531.	2.2	7

#	ARTICLE	IF	CITATIONS
332	Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: Data from 17 Clinical Trials with Over 18,000 Patient-Years of Exposure. <i>Dermatology and Therapy</i> , 2022, 12, 1431-1446.	3.0	7
333	Patient perceptions of psoriatic disease in Japan: Results from the Japanese subgroup of the Understanding Psoriatic Disease Leveraging Insights for Treatment (<scp>UPLIFT</scp>) survey. <i>Journal of Dermatology</i> , 0, , .	1.2	2
334	Ustekinumab Treatment in Patients with Moderate-to-Severe Psoriasis and Latent Tuberculosis Infection: A Study of 3 Case Reports. <i>Journal of Cosmetics Dermatological Sciences and Applications</i> , 2022, 12, 95-99.	0.2	1
335	Treatment of hidradenitis suppurativa resolves associated hematologic abnormalities. <i>International Journal of Women's Dermatology</i> , 2022, 8, e011.	2.0	0
336	Occurrence of inflammatory bowel disease in patients with chronic inflammatory skin diseases: a cohort study. <i>British Journal of Dermatology</i> , 2022, 187, 692-703.	1.5	19
337	Part I: Interactive case: Psoriasis. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2022, 5, 644-648.	1.0	0
338	Combination Therapy with Apremilast and Biologics for Psoriasis: A Systematic Review. <i>American Journal of Clinical Dermatology</i> , 0, , .	6.7	7
339	Endothelial Dysfunction in Psoriasis: An Updated Review. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	12
340	The utility of frequent laboratory monitoring for patients on tumor necrosis factor-alpha inhibitors in dermatology. <i>Kansas Journal of Medicine</i> , 2022, 15, 212-214.	0.4	0
341	Efficacy and Safety of Apremilast in the Treatment of Patients with Mild-to-Moderate Psoriasis in Japan: Results from PROMINENT, A Phase 3b, Open-Label, Single-Arm Study. <i>Dermatology and Therapy</i> , 2022, 12, 1469-1480.	3.0	4
342	Cardiometabolic multimorbidity is common among patients with psoriasis and is associated with poorer outcomes compared to those without comorbidity. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2975-2982.	2.2	2
343	The use of nonâ€œtransplant biologics in solid organ transplant recipients: A practical review for the frontline clinician. <i>Clinical Transplantation</i> , 2022, 36, .	1.6	1
344	Efficacy and Safety of Ixekizumab in Chinese Patients With Moderate-to-Severe Plaque Psoriasis: 60-Week Results From a Phase 3 Study. <i>International Journal of Dermatology and Venereology</i> , 2022, 5, 181-190.	0.3	3
345	The seroconversion rate of QuantiFERON-TB gold in-tube test in psoriatic patients receiving anti-interleukin-23 monoclonal antibodies. <i>Dermatologica Sinica</i> , 2022, 40, 94.	0.5	3
346	Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational <i>psoriasis study of health outcomes</i> (<scp>PSoHO</scp>). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 2087-2100.	2.4	15
347	Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: A systematic review, meta-analysis, and expert opinion. <i>Journal of Hepatology</i> , 2022, 77, 1670-1689.	3.7	26
348	Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis. <i>Dermatology and Therapy</i> , 2022, 12, 1777-1792.	3.0	22
349	Psoriasis and Exercise: A Review. <i>Psoriasis: Targets and Therapy</i> , 0, Volume 12, 189-197.	2.2	4

#	ARTICLE	IF	CITATIONS
350	Vaccine-induced erythrodermic psoriasis in a child successfully treated with secukinumab: A case report and brief literature review. <i>Dermatologic Therapy</i> , 2022, 35, .	1.7	5
351	The immunoregulatory effects of natural products on psoriasis via its action on Th17 cells versus regulatory T cells balance. <i>International Immunopharmacology</i> , 2022, 110, 109032.	3.8	13
352	Review of dermatologic medications and impact on male fertility, sexual dysfunction and teratogenicity. <i>Andrology</i> , 2022, 10, 1272-1285.	3.5	2
353	Efficacy, Safety, and Pharmacoeconomic Analysis of Adalimumab and Secukinumab for Moderate-to-Severe Plaque Psoriasis: A Single-Center, Real-World Study. <i>Dermatology and Therapy</i> , 0, , .	3.0	2
354	Reply to: "Routine re-screening for latent tuberculosis has low utility in patients with chronic immune-mediated inflammatory diseases treated with biologics: a single-center retrospective cohort study". <i>Journal of the American Academy of Dermatology</i> , 2022, , .	1.2	0
355	"Transfersome-embedded-gel"™ for dual-mechanistic delivery of anti-psoriatic drugs to dermal lymphocytes. <i>Journal of Microencapsulation</i> , 2022, 39, 495-511.	2.8	4
356	Real World Studies of Psoriasis and Mental Illness in Newfoundland and Labrador. <i>Journal of Cutaneous Medicine and Surgery</i> , 0, , 120347542211177.	1.2	1
357	Efficacy and safety of biological agents for the treatment of pediatric patients with psoriasis: A bayesian analysis of six high-quality randomized controlled trials. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	4
358	Preoperative Management of Medications for Rheumatologic and HIV Diseases: Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement. <i>Mayo Clinic Proceedings</i> , 2022, 97, 1551-1571.	3.0	3
359	Impact of secukinumab on patient-reported outcomes in biologic-naïve patients with psoriasis in a US real-world setting. <i>Journal of Dermatological Treatment</i> , 2022, 33, 3178-3187.	2.2	1
360	Management of moderate-to-severe plaque psoriasis with biologics: A treatment target position paper. <i>Dermatologic Therapy</i> , 2022, 35, .	1.7	2
361	Real-world data on the use of secukinumab and acitretin in pediatric generalized pustular psoriasis. <i>Journal of Dermatology</i> , 2023, 50, 258-261.	1.2	6
362	Management of Coexisting Bullous Pemphigoid and Psoriasis: A Review. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 869-879.	6.7	8
364	Treatment Patterns for Targeted Therapies, Non-Targeted Therapies, and Drug Holidays in Patients with Psoriasis. <i>Dermatology and Therapy</i> , 2022, 12, 2087-2103.	3.0	2
365	Successful use of <scp>anti-IL</scp> 23 molecules in overweight-to-obese psoriatic patients: A multicentric retrospective study. <i>Dermatologic Therapy</i> , 2022, 35, .	1.7	8
366	The imbalance between Type 17 T-cells and regulatory immune cell subsets in psoriasis vulgaris. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	12
367	Cytokine Modulators in Plaque Psoriasis—A Review of Current and Prospective Biologic Therapeutic Approaches. <i>JAAD International</i> , 2022, 9, 82-91.	2.2	2
368	Efficacy and safety of treatment of moderate and severe psoriasis with the interleukin 23 inhibitor risankizumab. <i>Vestnik Dermatologii i Venerologii</i> , 2022, 98, 23-30.	0.6	0

#	ARTICLE	IF	CITATIONS
369	The impact of nail psoriasis on disease activity, quality of life, and clinical variables in patients with psoriatic arthritis: A cross-sectional multicenter study. International Journal of Rheumatic Diseases, 2023, 26, 43-50.	1.9	2
370	Biologics-Loaded Photothermally Dissolvable Hyaluronic Acid Microneedle Patch for Psoriasis Treatment. Advanced Functional Materials, 2022, 32, .	14.9	21
371	An anchored matching-adjusted indirect comparison of fixed-dose combination calcipotriol and betamethasone dipropionate (Cal/BDP) cream versus Cal/BDP foam for the treatment of psoriasis. Journal of Dermatological Treatment, 2022, 33, 3191-3198.	2.2	4
372	Generalized pustular psoriasis is a disease distinct from psoriasis vulgaris: evidence and expert opinion. Expert Review of Clinical Immunology, 2022, 18, 1033-1047.	3.0	20
373	A consensus-based approach on the management of patients with both psoriasis and psoriatic arthritis in the dermatological and rheumatological settings in Italy: The ADOI PSO-Amore Project. Dermatology Reports, 2022, 14, .	0.8	1
374	Roflumilast for Chronic Plaque Psoriasis. JAMA - Journal of the American Medical Association, 2022, 328, 1049.	7.4	6
375	Impact of COVID-19 Pandemic on Initiation of Immunosuppressive Treatment in Immune-Mediated Inflammatory Diseases in Austria: A Nationwide Retrospective Study. Journal of Clinical Medicine, 2022, 11, 5308.	2.4	3
376	A retrospective, single-center cohort study on complications after dental extractions in patients taking biologic agents. Journal of the American Dental Association, 2022, , .	1.5	0
377	Paradoxical improvement of life quality in the COVID-19 era in psoriasis patients. PLoS ONE, 2022, 17, e0275293.	2.5	1
378	Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis). Journal of the European Academy of Dermatology and Venereology, 2023, 37, 93-103.	2.4	19
379	Efficacy and safety of apremilast in patients with mild-to-moderate psoriasis up to 32 weeks: Results from the extension phase of the randomized, phase 3 ADVANCE trial. Journal of the American Academy of Dermatology, 2023, 88, 430-433.	1.2	1
380	Real-World Experience of Secukinumab in Moderate to Severe Psoriasis Patients in Thailand: Characteristics, Effectiveness, and Safety. Dermatologic Therapy, 0, , .	1.7	2
381	Anti-IL 23 biologics for the treatment of plaque psoriasis. Expert Opinion on Biological Therapy, 2022, 22, 1489-1502.	3.1	7
383	Treatment of Psoriasis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations. Journal of Rheumatology, 2023, 50, 131-143.	2.0	4
384	An update on emerging immunological targets and their inhibitors in the treatment of psoriasis. International Immunopharmacology, 2022, 113, 109341.	3.8	5
385	Current and emerging biologic and small molecule systemic treatment options for psoriasis and psoriatic arthritis. Current Opinion in Pharmacology, 2022, 67, 102292.	3.5	4
386	IL-23 Inhibitors for Moderate-to-Severe Plaque Psoriasis: A Review of Clinical Efficacy, Safety, and Tolerability. EMJ Dermatology, 0, , 112-123.	0.0	0
387	Biologic Treatment of Psoriasis and Tuberculosis Testing: A Retrospective Analysis. SKIN the Journal of Cutaneous Medicine, 2022, 6, 502-506.	0.3	0

#	ARTICLE	IF	CITATIONS
388	2022 Taiwanese Dermatological Association (TDA), Taiwanese Association for Psoriasis and Skin Immunology (TAPSI), and Taiwan Society of cardiology (TSOC) joint consensus recommendations for the management of psoriatic disease with attention to cardiovascular comorbidities. Journal of the Formosan Medical Association, 2023, 122, 442-457.	1.7	4
389	Deucravacitinib in moderate-to-severe psoriasis. Immunotherapy, 0, , .	2.0	1
390	A Review of the Safety of Interleukin-17A Inhibitor Secukinumab. Pharmaceuticals, 2022, 15, 1365.	3.8	13
391	Interim Clinical Utility Findings of a Transcriptomic Psoriasis Biologic Test Demonstrate Altered Physician Prescribing Behavior and Improved Patient Outcomes. SKIN the Journal of Cutaneous Medicine, 2022, 6, 458-462.	0.3	0
393	Kaempferol modulates IFN- γ induced JAK-STAT signaling pathway and ameliorates imiquimod-induced psoriasis-like skin lesions. International Immunopharmacology, 2023, 114, 109585.	3.8	7
394	Interleukin-12 and -23 Targeted Agents. , 2022, , 199-217.		0
395	Hepatitis Viruses. , 2022, , 431-450.		0
396	High Serum Level of TNF- α in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Open Access Macedonian Journal of Medical Sciences, 2022, 10, 2290-2295.	0.2	0
397	Novel and Off-Label Biologic Use in the Management of Hidradenitis Suppurativa, Pyoderma Gangrenosum, Lichen Planus, and Seborrheic Dermatitis: A Narrative Review. Dermatology and Therapy, 2023, 13, 77-94.	3.0	3
398	Effectiveness of Guselkumab Therapy among Patients with Plaque Psoriasis with Baseline IGA Score ≤ 2 in the CorEvitas Psoriasis Registry. Dermatology and Therapy, 2023, 13, 487-504.	3.0	4
399	Nanoparticles for Topical Application in the Treatment of Skin Dysfunctions—An Overview of Dermo-Cosmetic and Dermatological Products. International Journal of Molecular Sciences, 2022, 23, 15980.	4.1	18
401	Early intervention in psoriasis: Where do we go from here?. Frontiers in Medicine, 0, 9, .	2.6	2
402	Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2). Dermatology and Therapy, 2023, 13, 315-328.	3.0	2
403	National consensus on biologic dose reduction in psoriasis: a modified eDelphi procedure. Journal of Dermatological Treatment, 2023, 34, .	2.2	0
404	Role of tyrosine kinase 2 signals during progression of psoriasis. Exploration of Immunology, 0, , 760-770.	0.3	0
405	Dual targeting of mTOR/IL-17A and autophagy by fisetin alleviates psoriasis-like skin inflammation. Frontiers in Immunology, 0, 13, .	4.8	5
406	Review of Dual Biologics in Specialty Pharmacy Practice. Annals of Pharmacotherapy, 2023, 57, 1094-1110.	1.9	1
407	Economic Evaluation of Selected Interleukin Inhibitors Versus Methotrexate for Moderate-to-Severe Plaque Psoriasis From the Philippine Payer Perspective. Value in Health Regional Issues, 2023, 34, 100-107.	1.2	1

#	ARTICLE	IF	CITATIONS
408	Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial. <i>British Journal of Dermatology</i> , 2023, 188, 22-31.	1.5	8
409	Interleukin-17A Inhibitor Secukinumab Treatment in HIV-Positive Psoriasis Patient: A Case Report. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 0, Volume 15, 2949-2956.	1.8	4
410	Real-World Effectiveness of 9â€“12ÂMonths of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry. <i>Dermatology and Therapy</i> , 2023, 13, 629-640.	3.0	1
411	English version of Japanese guidance for use of biologics for psoriasis (the 2022 version). <i>Journal of Dermatology</i> , 2023, 50, .	1.2	12
412	Characterizing risk factors for hospitalization for psoriasis patients. <i>Archives of Dermatological Research</i> , 0, , .	1.9	0
413	When should systemic biologic therapy for psoriasis be discontinued?. <i>Journal of Dermatological Treatment</i> , 2023, 34, .	2.2	0
414	Benvitimod inhibits MCM6-mediated proliferation of keratinocytes by regulating the JAK/STAT3 pathway. <i>Journal of Dermatological Science</i> , 2023, 109, 71-79.	1.9	5
415	Dietary inflammatory potential and psoriasis: A crossâ€“sectional study. <i>Journal of Dermatology</i> , 2023, 50, 692-699.	1.2	2
416	Analysis of Drug Utilization in Patients with Psoriasis: A Real-World Retrospective Study Among the Italian Population. <i>Psoriasis: Targets and Therapy</i> , 0, Volume 13, 1-9.	2.2	3
417	Criteria used to define tumor necrosis factor-alpha inhibitors failure in patients with moderate-to-severe psoriasis: a systematic literature review. <i>Annals of Medicine</i> , 2023, 55, 1335-1345.	3.8	1
418	Does bimekizumab stand the test of time for psoriasis?. <i>British Journal of Dermatology</i> , 2023, 188, 5-6.	1.5	0
419	Realâ€“life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104â€“week multicenter retrospective study â€“ <sc>IL PSO</sc> (<sc>ITALIAN) Tj ETQq1 1 0.784314 2.4 18	2.4	18
420	Methodology of the brodalumab assessment of hazards: a multicentre observational safety (BRAHMS) study. <i>BMJ Open</i> , 2023, 13, e066057.	1.9	0
421	Matching-adjusted indirect comparison (MAIC) results confirmed by head-to-head trials: a case study in psoriasis. <i>Journal of Dermatological Treatment</i> , 2023, 34, .	2.2	0
422	Current management of generalized pustular psoriasis. <i>Experimental Dermatology</i> , 2023, 32, 1204-1218.	2.9	16
424	Real-world treatment patterns and healthcare costs in patients with psoriasis taking systemic oral or biologic therapies. <i>Journal of Dermatological Treatment</i> , 2023, 34, .	2.2	2
425	A discrete choice experiment on oral and injection treatment preferences among moderateâ€“toâ€“severe psoriasis patients in Japan. <i>Journal of Dermatology</i> , 2023, 50, 766-777.	1.2	5
426	Pilihan Pengobatan Sistemik pada Psoriasis. , 2022, 49, 164-169.		0

#	ARTICLE	IF	CITATIONS
427	The Potential Role of Etanercept in the Management of Post-stroke Pain: A Literature Review. Cureus, 2023, , .	0.5	0
428	Estimate of the cost per responder for treatment with biological therapies of moderate-to-severe plaque psoriasis in Colombia for first-year and maintenance periods. Expert Review of Pharmacoeconomics and Outcomes Research, 2023, 23, 511-517.	1.4	0
429	The Effectiveness of Guselkumab by BMI Category Among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry. Advances in Therapy, 2023, 40, 2493-2508.	2.9	1
430	Interleukin-17 and Tumor Necrosis Factor Show a Functional Hierarchy to Regulate the Production of Matrix Metalloproteases by Monocytes from Patients with Psoriasis. Journal of Interferon and Cytokine Research, 2023, 43, 140-146.	1.2	0
431	Development of Psoriasis Assessment Tools Among Patients in the CorEvitas Psoriasis Registry. Journal of Psoriasis and Psoriatic Arthritis, 2023, 8, 74-82.	0.7	0
432	APOA4 as a novel predictor of prognosis in Stevens-Johnson syndrome/toxic epidermal necrolysis: A proteomics analysis from two prospective cohorts. Journal of the American Academy of Dermatology, 2023, , .	1.2	0
433	IL-17 inhibitor-associated inflammatory bowel disease: A study based on literature and database analysis. Frontiers in Pharmacology, 0, 14, .	3.5	16
434	Paradoxical Reactions to Anti-TNF± and Anti-IL-17 Treatment in Psoriasis Patients: Are Skin and/or Gut Microbiota Involved?. Dermatology and Therapy, 2023, 13, 911-933.	3.0	9
435	Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA. Dermatology and Therapy, 2023, 13, 1053-1068.	3.0	3
437	Immunology of the Skin. , 2023, , 295-305.		1
438	Safety of guselkumab treatment for up to 5â€¦years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposure. British Journal of Dermatology, 2023, 189, 42-52.	1.5	7
439	Real-world dose escalation of biologics for moderate-to-severe psoriasis in the United States. Journal of Dermatological Treatment, 2023, 34, .	2.2	0
440	Realâ€¦world systemic treatment of patients with psoriasis: A retrospective study based on German claims data. JDDG - Journal of the German Society of Dermatology, 2023, 21, 611-619.	0.8	6
441	Brodalumab for Plaque Psoriasis: A Canadian Real-World Experience at 2-Years Post-Launch. Journal of Cutaneous Medicine and Surgery, 2023, 27, 226-235.	1.2	1
442	Management of adult generalized pustular psoriasis using biologics: A systematic review. Journal of the American Academy of Dermatology, 2023, 89, 417-419.	1.2	4
443	Efficacy and safety of supramolecular active zinc in the treatment of scalp psoriasis: A multicenter, randomized, observed-blind, parallel-group, placebo- and active-controlled non-inferiority trial. Clinical and Experimental Dermatology, 0, , .	1.3	0
444	Real-world switching patterns and associated characteristics in patients with psoriasis treated with biologics in the United States. Journal of Dermatological Treatment, 2023, 34, .	2.2	5
445	Breakthroughs and bottlenecks of psoriasis therapy: Emerging trends and advances in lipid based nano-drug delivery platforms for dermal and transdermal drug delivery. Journal of Drug Delivery Science and Technology, 2023, 84, 104548.	3.0	1

#	ARTICLE	IF	CITATIONS
446	Comparison of time-course, dose-effect, influencing factors and adverse events of biologics in the treatment of adults with moderate to severe plaque psoriasis. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	1
447	Suboptimal Clinical and Quality of Life Outcomes in Patients with Psoriasis Undertreated with Oral Therapies: International Physician and Patient Survey. <i>Dermatology and Therapy</i> , 2023, 13, 1289-1303.	3.0	0
448	Pathology and Treatment of Psoriasis Using Nanoformulations. <i>Biomedicines</i> , 2023, 11, 1589.	3.2	2
449	A Retrospective Study of Time to Relapse following Guselkumab Withdrawal in Patients with Psoriasis. <i>Dermatologic Therapy</i> , 2023, 2023, 1-5.	1.7	0
450	Basic Therapeutic Approach for Patients with Plaque Psoriasis: Korean Expert Consensus Using the Modified Delphi Method. <i>Annals of Dermatology</i> , 2023, 35, 173.	0.9	0
451	Pso-Reg: a web registry for psoriasis in real life. <i>Italian Journal of Dermatology and Venereology</i> , 2023, 158, .	0.2	0
452	Safety of current systemic therapies for nail psoriasis. <i>Expert Opinion on Drug Safety</i> , 2023, 22, 391-406.	2.4	1
453	Systemische Behandlung von Patienten mit Psoriasis in der tglichen Praxis: Eine retrospektive Studie auf Basis deutscher Krankenkassendaten. <i>JDDG - Journal of the German Society of Dermatology</i> , 2023, 21, 611-621.	0.8	0
454	Risk of all-cause and cause-specific mortality associated with immune-mediated inflammatory diseases in Korea. <i>Frontiers in Medicine</i> , 0, 10, .	2.6	0
455	The PI3K-Akt-mTOR and Associated Signaling Pathways as Molecular Drivers of Immune-Mediated Inflammatory Skin Diseases: Update on Therapeutic Strategy Using Natural and Synthetic Compounds. <i>Cells</i> , 2023, 12, 1671.	4.1	9
456	Realâ€world efficacy of adjunctive calcipotriene/betamethasone dipropionate foam for recalcitrant psoriatic lesions on the scalp or lower legs with biologic therapy. <i>Journal of Dermatology</i> , 0, , .	1.2	0
457	Dermatologic barriers to deployment: Ethical considerations when treating military service members. <i>Journal of the American Academy of Dermatology</i> , 2023, , .	1.2	1
458	A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study of Tildrakizumab Efficacy and Safety in Patients With Active Ankylosing Spondylitis. <i>Journal of Clinical Rheumatology</i> , 2023, 29, 223-229.	0.9	1
459	Patient and Physician Perceptions of Psoriatic Disease in the United States: Results from the UPLIFT Survey. <i>Dermatology and Therapy</i> , 2023, 13, 1329-1346.	3.0	1
460	Psoriasis: overview, treatments and implications for nursing care. <i>British Journal of Nursing</i> , 2023, 32, 462-465.	0.7	0
461	The correlation of psoriasis and its treatment medications with lumbar discectomy postoperative infections. <i>Spine Journal</i> , 2023, 23, 1623-1629.	1.3	1
462	Impact of Gut Bacterial Metabolites on Psoriasis and Psoriatic Arthritis: Current Status and Future Perspectives. <i>Journal of Investigative Dermatology</i> , 2023, , .	0.7	0
463	Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program. <i>Dermatology and Therapy</i> , 2023, 13, 1831-1846.	3.0	0

#	ARTICLE	IF	CITATIONS
464	A retrospective review of the management of patients following a malignancy diagnosis on biologic therapies for the treatment of dermatological disorders. JAAD Case Reports, 2023, 39, 81-87.	0.8	0
466	Sociodemographic and clinical characteristics associated with multiple biologic failure in psoriasis: A 2015-2022 prospective cohort analysis of the CorEvitas psoriasis registry. Journal of the American Academy of Dermatology, 2023, 89, 974-983.	1.2	1
467	Calcipotriene and Betamethasone Dipropionate PAD-Cream Demonstrates Greater Treatment Efficacy in Patients with Moderate-to-Severe Psoriasis Compared to Topical Suspension/Gel: A Subgroup Analysis of Two Phase-3 Studies. Dermatology and Therapy, 0, , .	3.0	0
468	Tapinarof cream 1% in plaque psoriasis: a profile of its use. Drugs and Therapy Perspectives, 0, , .	0.6	0
469	A Survey of Nurse Practitioner and Physician Assistant Advanced Practice Providers Uncovers a Need for Precision Medicine in Psoriasis Management. , 2023, 17, .		0
470	The association between psoriasis and suicide. Dermatological Reviews, 0, , .	0.5	0
471	Initiation patterns among novel systemic agents for US adults with psoriasis and psoriatic arthritis: a retrospective cohort study. Archives of Dermatological Research, 0, , .	1.9	0
472	A Propensity Score-Matched Study on the Changes of TB Status and TB-IGRA Values in Patients with Psoriasis with Latent TB Receiving Secukinumab. Dermatology and Therapy, 0, , .	3.0	1
473	The economic burden and quality of life of patients with psoriasis treated with biologics in China. Journal of Dermatological Treatment, 2023, 34, .	2.2	1
474	Challenges and Future Trends in the Treatment of Psoriasis. International Journal of Molecular Sciences, 2023, 24, 13313.	4.1	10
475	Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review. Dermatology and Therapy, 2023, 13, 2171-2185.	3.0	0
476	Burden of Herpes Zoster Among Patients with Psoriasis in the United States. Dermatology and Therapy, 2023, 13, 2649-2668.	3.0	1
477	Should Cervical Cancer Screening with Papanicolaou Smear be Recommended for Female Patients with Psoriasis before Biological Agent Treatment?. , 2023, 126, 457-461.		0
478	Elevated serum IL-6 levels predict treatment interruption in patients with moderate to severe psoriasis: a 6-year real-world cohort study. Anais Brasileiros De Dermatologia, 2024, 99, 34-42.	1.1	1
480	Deucravacitinib: A Novel TYK2 Inhibitor for the Treatment of Moderate-to-Severe Psoriasis. Journal of Psoriasis and Psoriatic Arthritis, 2023, 8, 156-165.	0.7	0
481	[Translated article] Selection of Quality Indicators for the Certification of Psoriasis Units: The CUDERMA Project Delphi Consensus Study. Actas Dermo-sifiliográficas, 2023, 114, T865-T883.	0.4	0
482	Optimization of secukinumab dose regimens in patients with moderate-to-severe plaque psoriasis via exposure-response modeling. Expert Review of Clinical Pharmacology, 2023, 16, 999-1008.	3.1	0
483	Multivariate Mendelian randomization provides no evidence for causal associations among both psoriasis and psoriatic arthritis, and skin cancer. Frontiers in Immunology, 0, 14, .	4.8	0

#	ARTICLE	IF	CITATIONS
484	Skin Clearance is Associated with Reduced Treatment Failure in Patients with Psoriasis: Real-World Evidence from the CorEvitas Psoriasis Registry. <i>Dermatology and Therapy</i> , 0, , .	3.0	0
485	Efficacy and safety of spesolimab for the management of generalized pustular psoriasis: a drug safety evaluation. <i>Expert Opinion on Drug Safety</i> , 2023, 22, 1003-1010.	2.4	2
486	Efficacy and safety assessment of netakimab in scalp psoriasis. <i>Meditinskiy Sovet</i> , 2023, , 53-60.	0.5	0
487	Comparison of a second TNFi vs other biologic or targeted synthetic DMARD following an initial TNFi. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2023, 29, 1109-1118.	0.9	0
488	Erythroderma. , 2023, , 311-328.		0
489	Management of Pediatric Psoriasis: A U.S. Survey Based on Visits from the National Ambulatory Medical Care Survey (NAMCS). <i>Dermatology and Therapy</i> , 0, , .	3.0	0
490	Diagnosis and Management of Common Inflammatory Skin Diseases in Older Adults. <i>Clinics in Geriatric Medicine</i> , 2023, , .	2.6	0
491	Exploring the Clinical Assessment, Guidelines, and Options for the Treatment of Generalized Pustular Psoriasis [Podcast]. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 0, Volume 16, 2911-2917.	1.8	1
492	Is anti-IL-17 faster and anti-IL-23 better for psoriasis patients after adalimumab failure?. , 2024, 3, 331-332.		0
493	Discontinuation of anti-TNF-alpha treatment due to blood test abnormalities and cost-effectiveness of alternate blood monitoring strategies. <i>British Journal of Dermatology</i> , 0, , .	1.5	1
494	A systematic review investigating at what proportion clinical images are shared in prospective randomized controlled trials involving patients with psoriasis and biological agents. <i>Journal of Dermatological Treatment</i> , 2023, 34, .	2.2	0
495	Deucravacitinib in plaque psoriasis: a profile of its use. <i>Drugs and Therapy Perspectives</i> , 2023, 39, 357-364.	0.6	0
496	Targeting cyclin-dependent kinases in rheumatoid arthritis and psoriasis â€” a review of current evidence. <i>Expert Opinion on Therapeutic Targets</i> , 2023, 27, 1097-1113.	3.4	0
497	Resveratrol and Its Derivatives in Inflammatory Skin Disordersâ€”Atopic Dermatitis and Psoriasis: A Review. <i>Antioxidants</i> , 2023, 12, 1954.	5.1	2
498	Roflumilast 0.3% Cream: a Phosphodiesterase 4 Inhibitor for the Treatment of Chronic Plaque Psoriasis. <i>American Journal of Therapeutics</i> , 2023, 30, e535-e542.	0.9	1
499	Features of Cell-Mediated Immunity in Children with Congenital Ichthyosis and Their Role in the Pathogenetic Management. <i>Voprosy Sovremennoi Pediatrii - Current Pediatrics</i> , 2023, 22, 415-424.	0.4	0
500	Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS). <i>Journal of the American Academy of Dermatology</i> , 2024, 90, 494-503.	1.2	2
501	Comorbidity Burden and Treatment Patterns of Psoriasis in Vietnam: Real-World Data from the EXPAND Study. <i>Dermatology and Therapy</i> , 2023, 13, 3193-3208.	3.0	0

#	ARTICLE	IF	CITATIONS
502	Non-pharmacological interventions for patients with psoriasis: a scoping review. <i>BMJ Open</i> , 2023, 13, e074752.	1.9	0
503	Tapinarof cream 1% once daily for the treatment of adults with mild to severe plaque psoriasis: A novel topical therapy targeting the aryl hydrocarbon receptor. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2023, 29, S2-S14.	0.9	0
504	Self-management of psoriasis vulgaris treatment burden: A Review. <i>Medicine (United States)</i> , 2023, 102, e35392.	1.0	0
505	Advancements in the Study of Biologic Agents in Comorbidities of Psoriasis: A Literature Review. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 0, Volume 16, 3487-3495.	1.8	0
506	Tapinarof cream 1% once daily for the treatment of adults with mild to severe plaque psoriasis: A novel topical therapy targeting the aryl hydrocarbon receptor. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2023, 29, S1-S14.	0.9	0
507	Comparative effectiveness and cost evaluation of Risankizumab and Adalimumab in the management of psoriasis: a real-world study in Saudi Arabia. <i>Cost Effectiveness and Resource Allocation</i> , 2023, 21, .	1.5	0
508	An international Delphi consensus to define a clinically appropriate definition of disease modification for plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 0, , .	2.4	0
509	Experience of using the interleukin-17A inhibitor secukinumab in the treatment of psoriasis and psoriatic arthritis. <i>Russian Journal of Skin and Venereal Diseases</i> , 2023, 26, 563-574.	0.2	0
510	A new approach in monitoring blood tests in anti-TNF- $\hat{\pm}$ therapies in psoriasis. <i>British Journal of Dermatology</i> , 0, , .	1.5	0
511	Identifying therapeutic alternatives in Medicare drug price negotiation: The case of etanercept. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2024, 30, 226-233.	0.9	0
512	Incidence of New-Onset Inflammatory Bowel Disease, Oral and Gastrointestinal Candidiasis, Herpes Zoster, Pulmonary Tuberculosis, and Major Cardiovascular Events in Patients with Moderate-to-Severe Psoriasis Exposed to Biologics. <i>Journal of Clinical Medicine</i> , 2023, 12, 7653.	2.4	1
513	Systemic sclerosis is a risk factor of incident psoriasis: results from a nationwide cohort study. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	1
514	Global trends and research status in ankylosing spondylitis clinical trials: a bibliometric analysis of the last 20 years. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
515	Immune cells in the epithelial immune microenvironment of psoriasis: emerging therapeutic targets. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	1
516	Tildrakizumab for moderate-to-severe plaque psoriasis in Chinese patients: A 12-week randomized placebo-controlled phase III trial with long-term extension. <i>Chinese Medical Journal</i> , 0, , .	2.3	0
517	The Effects of Cardiometabolic Comorbidities on Biologic Treatment for Psoriasis with Respect to PASI Scores: A Qualitative Systematic Review. <i>Psoriasis: Targets and Therapy</i> , 0, Volume 14, 1-10.	2.2	0
518	Assessment of safety profile of secukinumab in real-world scenario using United States food and drug administration adverse event reporting system database. <i>Scientific Reports</i> , 2024, 14, .	3.3	1
519	The Saudi consensus recommendations for the management of psoriatic arthritis (2023). <i>Clinical Rheumatology</i> , 2024, 43, 879-894.	2.2	0

#	ARTICLE	IF	CITATIONS
520	Vaccinations in Selected Immune-Related Diseases Treated with Biological Drugs and JAK Inhibitors Literature Review and Statement of Experts from Polish Dermatological Society. Vaccines, 2024, 12, 82.	4.4	0
521	Infections in the era of immunobiologicals. Anais Brasileiros De Dermatologia, 2024, 99, 167-180.	1.1	0
522	Etiopathogenesis of Psoriasis: Integration of Proposed Theories. Immunological Investigations, 2024, 53, 348-415.	2.0	0
523	A Novel Multi-Strain E3 Probiotic Formula Improved the Gastrointestinal Symptoms and Quality of Life in Chinese Psoriasis Patients. Microorganisms, 2024, 12, 208.	3.6	0
525	Patient-Reported Outcome Measures for Health-Related Quality of Life in Patients With Psoriasis. JAMA Dermatology, 0, , .	4.1	0
526	Novel anti-psoriasis agent-associated cardiotoxicity, analysis of the FDA adverse event reporting system (FAERS). International Journal of Cardiology, 2024, 402, 131819.	1.7	0
527	Prevalence of Pretreatment Testing Recommended for Patients With Chronic Inflammatory Skin Diseases. JAMA Dermatology, 2024, 160, 334.	4.1	1
528	Adding Chinese herbal medicine bath therapy to conventional therapies for psoriasis vulgaris: A systematic review with meta-analysis of randomised controlled trials. Phytomedicine, 2024, 128, 155381.	5.3	0
529	<scp>Real world</scp> data on the effectiveness of brodalumab in patients with moderate to severe plaque psoriasis in the Greek clinical setting (the <scp>BrIDGE</scp> study). Journal of the European Academy of Dermatology and Venereology, 0, , .	2.4	0
530	Effectiveness and Safety of Biological Therapies in Very Severe Plaque Psoriasis: A Real-Life Retrospective Study. Journal of Personalized Medicine, 2024, 14, 186.	2.5	0
531	Consensus Guidelines: Best Practices for the Prevention, Detection and Management of Hepatitis B Virus Reactivation in Clinical Trials with Immunosuppressive/Immunomodulatory Therapy. Drug Safety, 2024, 47, 321-332.	3.2	0
532	Reduced economic disparity in biologics use for psoriasis after introducing the reducing copayment program. Scientific Reports, 2024, 14, .	3.3	0
533	Use of Efficiency Frontiers to Align Prices and Clinical Benefits of Biologic Therapies for Plaque Psoriasis. JAMA Dermatology, 2024, 160, 409.	4.1	0
534	Guselkumab in Patients with Scalp Psoriasis: A post hoc Analysis of the VOYAGE 2 Phase III Randomized Clinical Trial. Acta Dermato-Venereologica, 0, 104, adv18672.	1.3	0
535	Satisfaction with the Injection Experience of a New, Citrate-Free Formulation of Ixekizumab. Advances in Therapy, 2024, 41, 1672-1684.	2.9	0
536	Biologics for Psoriasis. Dermatologic Clinics, 2024, , .	1.7	0
537	EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Annals of the Rheumatic Diseases, 0, , ard-2024-225531.	0.9	0
538	TYK2: an emerging therapeutic target in rheumatic disease. Nature Reviews Rheumatology, 2024, 20, 232-240.	8.0	0

#	ARTICLE	IF	CITATIONS
539	Relevance of Adalimumab Product Attributes to Patient Experience in the Biosimilar Era: A Narrative Review. <i>Advances in Therapy</i> , 2024, 41, 1775-1794.	2.9	0
540	Phototherapy for Psoriasis in the Age of Biologics. <i>Dermatologic Clinics</i> , 2024, , .	1.7	0
541	Add-on effects of Chinese herbal medicine external application (FZHFZY) to topical urea for mild-to-moderate psoriasis vulgaris: Protocol for a double-blinded randomized controlled pilot trial embedded with a qualitative study. <i>PLoS ONE</i> , 2024, 19, e0297834.	2.5	0
542	<i>Coccidioides</i> Serologic Screening Practices in Individuals With Rheumatic and Autoimmune Diseases. <i>ACR Open Rheumatology</i> , 0, , .	2.1	0